ImmunityBio ISPOR data show why NMIBC treatment choices are becoming harder to standardize
Bladder cancer care is shifting from survival alone to treatment trade-offs. ImmunityBio’s NMIBC survey shows why preference now matters.
Pharma & Biotech
Pharma & Biotech
Why ImmunityBio’s ANKTIVA cost analysis could intensify the bladder cancer value debate
Bladder cancer drugs face a value test. ImmunityBio’s ANKTIVA analysis raises new questions on cost, response durability and access.